EMG
RGNX icon

Ellington Management Group’s Regenxbio RGNX Stock Holding History

Ellington Management Group’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,200
Closed -$216K – 757
2019
Q2 		$216K Buy
+4,200
New +$210K 0.04% 466
2017
Q3 		– Sell
-10,500
Closed -$207K – 814
2017
Q2 		$207K Buy
+10,500
New +$203K 0.03% 519

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ellington Management Group's RGNX Position: Q3 2019 in Review

Ellington Management Group sold out of Regenxbio (RGNX) in Q3 2019, closing a stake of 4,200 shares — an estimated $216K sold.

Ellington Management Group first reported a position in RGNX in Q2 2017 and held it in 2 quarters. The position peaked at $216K in Q2 2019. 168 funds tracked by Wall St. Rank hold RGNX as of Q3 2019.

  • Ellington Management Group reported no remaining Regenxbio position as of Q3 2019 after selling out during the quarter.
  • Ellington Management Group sold 4,200 Regenxbio shares in Q3 2019, an estimated $216K.
  • Ellington Management Group first reported a position in Regenxbio in Q2 2017 and held it in 2 quarters.
  • Ellington Management Group's Regenxbio position peaked at $216K in Q2 2019.
  • 168 funds tracked by Wall St. Rank held Regenxbio as of Q3 2019.

Based on Ellington Management Group's 13F filing for Q3 2019, filed 14 Nov 2019.